- Journalists Share Latest on Baby Formula Safety, Estrogen Patches, and Postcancer Costs
- 12 new behavioral health study findings to know
- Prevention Efforts Increasingly See Suicide Through a Broader Lens
- California dental hygiene program placed on probation, accreditation at risk: 5 notes
- US depression rate remains near record high: Gallup
- FDA names acting director of vaccines and biologics center
- We Are Breaking Anesthesia — And Calling It a Staffing Solution
- Establishing Good Governance: Start with the Important Basics and Play the Long Game
- Mission, margin and a midterm clock: Healthcare signals to watch
- What ASC tech actually moves the needle — and what’s just ‘face paint’
- ADA pushes for increased federal oversight of dental insurance: 4 notes
- VisionMed appoints new strategic advisor of ambulatory, office-based surgery
- South Dakota hospital joins Monument Health
- Dental groups call on legislators to support federal oral health programs
- PDS Health joins AARP global collaborative
- Nemours Children’s Health breaks ground on multispecialty facility
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
- Physician financial pressures, a breakdown
- Physicians’ wRVU problem, by the numbers
- CMS’ Medicare provider directory released Social Security numbers: Washington Post
- The best ASCs for colonoscopy, endoscopy in the Midwest: US News
- 2 post-acute groups react to bill to improve CNA training
- 32 hospitals closing departments or ending services
- Visa limbo drags on for hundreds of physicians: 5 notes
- Hygienist shortage a ‘retention’ crisis: ADHA
- Yale receives $10M for youth mental health
- PDS Health grows de novo network with 6 new practices
- Penn Medicine, CHOP name autism institute director
- Cleveland Clinic adds GI specialist
- FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
- A new kind of ASC partner has entered the market
- 8 DSOs making headlines
- Heartland Dental adds Florida practice
- Colorado behavioral health provider to cut 111 jobs
- High-Intensity Exercise After Breast Cancer Surgery Helps Speed Recovery
- SALT Dental Partners opens de novo office in Washington, DC
- Noncompete rules shift again: 4 recent updates
- The 4 states with the most DSO activity in April
- 10 new ASCs in April
- Florida physician sued for alleged $1.9M fraud
- Omada signs on with Optum Rx's GLP-1 management program
- Trump Offers Third Candidate For Surgeon General After Pulling Dr. Casey Means' Nomination
- Industry Voices—Value-based care won the policy argument. Now it has to deliver
- Senators introduce clean extension to cost-based payments for some rural hospitals
- Expanding access, improving outcomes: How AI is transforming behavioral health referrals
- Beth Israel Lahey Health taps Heidi for system-wide AI scribe rollout
- Johnson & Johnson Enters Agreement to Acquire Atraverse Medical
- Johnson & Johnson Enters Agreement to Acquire Atraverse Medical
- enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve
- enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve
- Medtronic Gains CE Mark for Stealth AXiS surgical system
- Medtronic Gains CE Mark for Stealth AXiS surgical system
- Medtronic Continues Cardiovascular Care Growth with Completion of CathWorks Acquisition
- Medtronic Continues Cardiovascular Care Growth with Completion of CathWorks Acquisition
- Cleveland Clinic taps startup Luminai to test how AI can run hospital operations
- Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
- Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
- Union workers at Korean CDMO Samsung Biologics kick off strike
- Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
- Who do Americans believe have the most influence in healthcare?
- Health Tech Weekly Rundown: Sage launches Tasking for senior care workflows; St. Luke’s taps Auxira Health for cardiologist support
- Confusion Continues Over Age To Start Breast Cancer Screening, Survey Finds
- Senses, Not Muscles, Key to Speech Recovery After Stroke
- Antibiotics Not Linked To Celiac Disease Risk, Study Argues
- Common Knee Surgery Doesn't Help, Might Actually Make Things Worse, Clinical Trial Reports
- States Rush To Figure Out How To Enforce Trump's Medicaid Work Requirements
- Delays in Visa Program Threaten Placement of Hundreds of Doctors in Underserved Areas
- Gavin Newsom, Early Champion of Single-Payer, Moderates in the Face of Fiscal Limits
- A pivotal time for an RNA pioneer
- Repatha sales help Amgen overcome Prolia biosimilar hits in 1st quarter
- Novo Nordisk’s Rybelsus officially retired in US as ‘Ozempic pill’ takes branding center stage
- Verastem launches ‘Reimagine’ campaign to move ovarian cancer drugs into earlier lines
- From Prototype to Production: Building a Validation Strategy That Scales with Manufacturing Volume
- From Prototype to Production: Building a Validation Strategy That Scales with Manufacturing Volume
- Mount Sinai launches mental health program for performing artists
- Managing AI in Medical Technology: From Innovation to Compliance
- Managing AI in Medical Technology: From Innovation to Compliance
- Mississippi to distribute $13.5M for youth mental health programs
- ‘Heroism doesn’t scale’: 4 leaders warn of cracks in behavioral health system
- Fierce Pharma Asia—Sun’s $11.75B Organon buy; Astellas’ Xtandi peak; BeOne’s PD-1xVEGF bet
- Seven Things Every Medical Device Manufacturer Must Know Before Integrating AI
- Seven Things Every Medical Device Manufacturer Must Know Before Integrating AI
- The Structural Tension at the Heart of MedTech
- The Structural Tension at the Heart of MedTech
- Cybersecurity Tactics for Medical IoT Devices
- Cybersecurity Tactics for Medical IoT Devices
- From Toddlers to Teens: The Hidden Complexities of Bringing Pediatric Wearables to Market
- From Toddlers to Teens: The Hidden Complexities of Bringing Pediatric Wearables to Market
- Drug use by state in 2026
- DOJ launches West Coast Health Care Strike Force to target fraud in Arizona, Nevada, Northern California
- Tenet Healthcare met Q1's volume curveballs with 'old-fashioned discipline'
- FDA expectations create potential friction in new Form 483 response guidance
- Trump pulls surgeon general nomination of Casey Means, names Nicole Saphier as new pick
- New Medical Guidelines Urge More Fiber, Less Bathroom Scrolling on Your Phone
- Sleep and Anxiety Medications in Pregnancy Appear to Pose Little Harm
- Functional medicine provider Parsley Health now in-network nationwide
- Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
- BMS 'well prepared' for Camzyos competition as revenue from new products overtakes legacy portfolio
- Waystar kicks off 2026 with strong growth as it targets AI at $100B RCM labor pool
- Merck's growth products Winrevair, Ohtuvayre trending in opposite directions
- Trump's Medicaid Work Mandate Debuting in Nebraska to Much Dismay
- Nasal Spray Flu Vaccines Create 'Battlefield' In Adults' Noses
- Prehabilitation Slashes Post-Op Complications By Half, Review Says
- Understanding Emotions Could Be Key To Quelling Chronic Pain
- Meth Caused 1 In 6 Heart Attacks Over A Decade, Study Finds
- States Rush To Figure Out How To Enforce Trump’s Medicaid Work Requirements
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- Photon, maker of modern prescription infrastructure, nabs $16M to scale
- Cigna to exit ACA market, pursue strategic alternatives for eviCore unit
- Amarox recalls batch of antidepressants in UK over packaging mix-up
- Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals'
- Merck bats for heart disease awareness with new baseball-inspired campaign
- Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs
- Europe’s drug regulator sets up new group to counter vaccine hesitancy
- Aidoc banks $150M backed by Goldman Sachs to scale clinical AI foundation model
- Healthcare costs remain a top concern for voters as midterms loom: KFF
- Nonprofit health systems are falling short on governance capabilities, report warns
- Novartis rounds out $23B US investment push with plans for North Carolina API plant
- Teladoc Health reports strong momentum behind BetterHelp insurance shift, CEO says
- AI Tool May Help Identify ADHD in Kids Long Before Typical Diagnosis
- Viz.ai partners with National Rural Health Association to expand AI understanding, access to rural hospitals
- FDA Moves to Real-Time Clinical Trial Patient Monitoring, Faster Drug Review
- AstraZeneca CEO's conservative MFN model excludes reference markets from forecast
- With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorphosis
- Universal Health Services' Q1 2026 earnings growth dampened by volume hits
- AbbVie outlines Skyrizi defense against new J&J plaque psoriasis rival Icotyde
- Only 1 in 4 employers able to ‘absorb’ increasing health benefit costs without impacting business
- Dementia Screening Safe For Families, Trial Finds
- Online Program Soothes Post-Trauma Stress In Injured Children
- Mental Defeat Can Worsen Chronic Pain, Researchers Say
- Pooled Umbilical Cord Blood Boosts Stem Cell Transplant Success, Trial Finds
- US drugmaker’s reputations shift quickly amid political pressures, job cuts: survey
- Saving Lives by Changing Lives: The Next Frontier in Suicide Prevention
- Trump’s Medicaid Work Mandate Debuting in Nebraska to Much Dismay
- The push to expand access to emergency contraception
- Secret to Surviving 'Perfect Mom' Posts on Social Media Revealed
- Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Getting All Your Ducks in a Row to IPO: Remarks at the Small Business Capital Formation Advisory Committee Meeting
- Remarks to the Small Business Capital Formation Advisory Committee
- CDC Warns of Antibiotic-Resistant Salmonella in Backyard Flocks
- Listen to the Latest ‘KFF Health News Minute’
- AI-driven coding platform Arintra rolls out new documentation improvement capabilities
- Florida Delays Children's Health Insurance Expansion as Uninsured Rate Rises
- Daylight Saving Time Fails to Boost Daily Steps, Study Finds
- Metabolic Syndrome Tied To Cancer Risk
- Mail-In Colon Cancer Test Kits Offer Affordable Screening
- U.S. Dentists Still Overprescribing Opioids Compared To Other Nations, Puerto Rico
- An Urgent Care Treated Her Allergic Reaction. An ER Monitored Her — For $6,700.
- Estrogen Patch Shortages Likely Driven By Empowered Women Seeking Relief, Expert Says
- First Gene Therapy for Genetic Hearing Loss, Otarmeni, Gains FDA Approval
Costco does not break out their pharmacy sales from their quarter trillion dollar overall sales, but their 614 U.S. warehouses are a major player in pharmaceutical sales:
Costco Says It Will Not Sell Abortion Pill Mifepristone
The company attributes its decision to lack of demand.
By Aldgra Fredly - August 15, 2025Costco Wholesale said on Aug.14 that it would maintain its stance of not selling the abortion pill mifepristone at its U.S. pharmacies due to low customer demand.
Mifepristone is a drug that blocks progesterone, the hormone needed for sustaining pregnancy. The Food and Drug Administration (FDA) approved the drug in 2000 for terminating pregnancy through 10 weeks of gestation, stating on its website that mifepristone is safe when used properly.
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the retailer said in a statement to multiple news outlets.
The move comes amid campaigns against the pill from faith-based groups, including exchange-traded fund provider Inspire Investing and legal advocacy group Alliance Defending Freedom (ADF).
ADF legal counsel Michael Ross applauded Costco for its decision.
“Retailers like Costco keep their doors open by selling a lifetime of purchases to families, both large and small. They have nothing to gain and much to lose by becoming abortion dispensaries,” Ross said in a statement.
Students for Life America (SFLA) praised the move as “a stunning win for life,” saying that it hopes more companies would follow Costco’s policy.
“Costco Wholesale insists its reason was not based on pressure from groups like ours,” SFLA stated. “We at PLG [pro-life generation] never expected an acknowledgement or public change of corporate heart on record. But we would still like to commend the pro-life movement for speaking sense into Costco Wholesale, resulting in saving the lives of the preborn and women.”
In May, Health Secretary Robert F. Kennedy Jr. ordered the FDA to review mifepristone after an analysis found that nearly 11 percent of women who took the drug experienced serious adverse events, including sepsis and hemorrhaging.
That percentage is higher than the summary figure of less than 0.5 percent in clinical trials reported on the drug label, according to the Ethics and Public Policy Center, which published the analysis.
“I think the new data … is alarming, and clearly it indicates that at the very least, the label should be changed,” Kennedy said on May 14.
In July 2024, New York City Comptroller Brad Lander sent letters to Costco and other retailers to dispense the abortion drug in states where it is legal. In his letter to Costco, Lander warned that failing to do so could raise “significant investor concerns,” noting that the New York City Retirement Systems held $443.9 million in Costco stock.
Several investment advisers and corporate engagement consultants representing investors who held $56 million in Costco stock sent a letter to the retailer urging it not to sell mifepristone.
Their petition received support from thousands of investors and customers.
Costco got lit up by one of their home state Senators for their decision not to sell mifepristone:
https://thehill.com/policy/healthcare/5455913-patty-murray-costco-abortion-pill-mifepristone/
Senate Democrat rips Costco for ‘refusing to sell’ abortion pills
By Steff Danielle Thomas - August 16, 2025Sen. Patty Murray (D-Wash.) hammered Costco on Friday for appeasing “far-right extremists,” after the retailer said earlier this week that its pharmacies would not dispense the abortion medication mifepristone.
“I am deeply alarmed by news reports that Costco is refusing to sell safe, effective, and legal medication for no other reason than to appease the politics of anti-abortion fanatics,” Murray said in a statement following the news. “I refuse to stand by and allow far-right extremists to bully major corporations and dictate what medicine women can or cannot get access to.”
“Where it is legal, retailers and major pharmacies must absolutely make medication abortion available to the women who need it,” the Washington Democrat added.
Costco, in its Thursday announcement, explained that the decision came from a “lack of demand.”
“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” the company said, according to Reuters.
The decision comes after CVS and Walgreens announced last year that they received certification to provide the drug in states where abortion remains legal.
Murray pressed Costco to rescind its decision, warning that limiting access to mifepristone, one of two drugs used in medication abortion, is harmful to women’s health.
“Mifepristone is safe and effective—we cannot live in a world where the availability of women’s health care whipsaws back and forth based on the whims of extremists who want to deny women access to basic health care,” she wrote Friday. “I am demanding that Costco immediately reverse course—follow the science and the facts, not the demands of far-right anti-abortion extremists.”
The Supreme Court in a decision last year ruled unanimously that a group of anti-abortion doctors did not have the legal basis to challenge access to the pill.
Despite the ruling, Health and Human Services Secretary Robert F. Kennedy Jr. and Food and Drug Administration (FDA) Commissioner Marty Makary are weighing a review of the abortion pill.
Murray questioned Makary during his Senate confirmation hearing on the proposal, as well as President Trump’s moves to gut staff at the FDA.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.
















